FDA again finds Amy­lyx's ALS da­ta lack­ing ahead of un­usu­al sec­ond ad­comm, while stress­ing dire need for treat­ments

The FDA’s brief­ing docs are in ahead of its un­usu­al sec­ond ad­comm for Amy­lyx Phar­ma­ceu­ti­cals’ ex­per­i­men­tal ALS drug next week — and the agency’s opin­ion is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER